Association between Paraoxonase-1 L55M Gene Polymorphism and Polycystic Ovarian Syndrome

Hiba Hayder Kadhum, Qasim Sharhan Al-mayah, Raid J. M. AL-Timimi, Fadia J Alizzi

Abstract


Background: Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder affecting women of reproductive age. Oxidative stress may contribute to its pathogenesis. Paraoxonase-1 (PON1) is an antioxidant enzyme associated with high-density lipoprotein, and its genetic polymorphisms may alter enzyme activity. This study aimed to investigate the association between PON1 L55M polymorphism (rs854560) and PCOS in Iraqi women.

Methods: This case-control study included 80 women aged 20–35 years who were in good general health   and matched for age and body mass index (BMI). Genomic DNA was extracted using a commercial kit. The PON1 L55M polymorphism was amplified by polymerase chain reaction and genotyped by direct sequencing. Statistical analysis was performed using SPSS version 25.

Results: No significant differences were observed between patients and controls regarding age or BMI. Genotype frequencies of rs854560 showed no significant differences between the two groups. Likewise, allele distribution was not significantly associated with PCOS (P > .05).

Conclusions: The PON1 L55M polymorphism was not associated with susceptibility to PCOS in this sample of Iraqi women. Further studies with larger sample sizes are recommended.

Keywords: PCOS, Paraoxonase-1, PON1, L55M, rs854560


Full Text:

PDF

References


Hima HA, Miah MAH, Ghosh NR, Sultana S, Akter T, et al. Nonalcoholic fatty liver disease in polycystic ovary syndrome: result of a single-center cross-sectional study in Bangladesh. Journal of Endocrinology and Metabolism, (2023);13(2): 80-87.

Borzan V, Lerchbaum E, Missbrenner C, Heijboer AC, Goschnik M, et al. Risk of insulin resistance and metabolic syndrome in women with hyperandrogenemia: a comparison between PCOS phenotypes and beyond. Journal of Clinical Medicine, (2021);10(4):829.

Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Human Reproduction Update, (2005);11(6):631-643.

Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: a multifaceted biomolecule. Clinica Chimica Acta, (2009);410(1-2):1-12.

Murillo-González F, Ponce-Ruiz N, Rojas-García A, Rothenberg S, Bernal-Hernández Y, et al. PON1 lactonase activity and its association with cardiovascular disease. Clinica Chimica Acta, (2020);500:47-53.

Taler-Ver?i? A, Goli?nik M, Bavec A. The structure and function of paraoxonase-1 and its comparison to paraoxonase-2 and -3. Molecules, (2020);25(24):5980.

Aslan M, Horoz M, Sabuncu T, Celik H, Selek S. Serum paraoxonase enzyme activity and oxidative stress in obese subjects. Polskie Archiwum Medycyny Wewnetrznej, (2011);121(6):181-186.

Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. Journal of Clinical Endocrinology and Metabolism, (2005);90(3):1728-1733.

Bayram F, Kocer D, Ozsan M, Muhtaroglu S. Evaluation of endothelial dysfunction and lipid metabolism in women with polycystic ovary syndrome: relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction. Gynecological Endocrinology, (2012);28(7):497-501.

Gurbuz T, Alanya Tosun S, Cebi A, Gokmen O, Usta M. Investigating Fetuin-A and paraoxonase-1 activity as markers in polycystic ovary syndrome based on body mass index: a prospective case-control study. Cureus, (2021);13(10):E18553.

Paltoglou G, Tavernarakis G, Christopoulos P, Vlassi M, Gazouli M, et al. PON1-108 TT and PON1-192 RR genotypes are more frequently encountered in Greek PCOS than non-PCOS women, and are associated with hyperandrogenaemia. Clinical Endocrinology, (2013);79(2):259-266.

Mohamed AA, Rashed LA, Salam RJ. Effect of paraoxonase gene polymorphisms on paraoxonase levels and insulin resistance index in women with polycystic ovary syndrome. Australian Journal of Basic and Applied Science, (2009);3(4):3346-3351.

Pau MC, Zinellu A, Zinellu E, Pintus G, Carru C, et al. Paraoxonase-1 concentrations in obstructive sleep apnoea: a systematic review and meta-analysis.Antioxidants, (2022);11(4):711.

Nalkiran HS, Sahin SB, Ayaz T, Nalkiran I, Guzel AI, et al. Association of paraoxonase-1 L55M and Q192R polymorphisms with PCOS risk and potential risk factors for atherosclerosis. Biomarkers in Medicine, (2019);13(4):279-289.

Wang Y, Liu H, Fan P, Bai H, Zhang J, et al. Evidence for association between paraoxonase 1 gene polymorphisms and polycystic ovarian syndrome in southwest Chinese women. European Journal of Endocrinology, (2012);166(5):877-885.

Kunjantarachot A, Pabalan N, Jarjanazi H, Christofolini DM, Montagna E, et al. Paraoxonase single nucleotide variants show associations with polycystic ovary syndrome: a meta-analysis. Reproductive Biology and Endocrinology, (2020);18(1):114.

Meneses MJ, Silvestre R, Sousa-Lima I, Macedo MP. Paraoxonase-1 as a regulator of glucose and lipid homeostasis: impact on the onset and progression of metabolic disorders. International Journal of Molecular Sciences, (2019);20(16):4049.

Motovali-Bashi M, Sedaghat S, Dehghanian F. Association between serum paraoxonase 1 activities (PONase/AREase) and L55M polymorphism in risk of female infertility. Avicenna Journal of Medical Biotechnology, (2015);7(4):173-178.

Saber SJM, Beyranvand H, Adibhesami G, Nouryazdan N. A brief review of the association between genetic polymorphisms of the paraoxonase family and atherosclerosis. International Journal of Medical Laboratory, (2022);9(2):100-109.

Costa LG, Richter RJ, Li WF, Cole T, Guizzetti M, et al. Paraoxonase (PON1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers, (2003);8(1):1-12.




DOI: https://doi.org/10.62940/als.v%25vi%25i.2669

Refbacks

  • There are currently no refbacks.